NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03197935,A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer,https://clinicaltrials.gov/study/NCT03197935,IMpassion031,COMPLETED,"This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).",YES,Triple-negative Breast Cancer,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|DRUG: Placebo|DRUG: Nab-paclitaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Filgrastim|DRUG: Pegfilgrastim","Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population, Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR., After neoadjuvant study treatment and surgery, up to primary analysis data cut off on 03 ApriI 2020|Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System, Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell \[IC\] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR., After neoadjuvant study treatment and surgery, up to primary analysis data cut off on 03 ApriI 2020","Event-Free Survival (EFS) in All Participants, Event-free survival (EFS) defined as the time from randomization to the first documented occurrence of disease recurrence, disease progression, or death from any cause in all participants. Recurrent disease includes local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or recurrent disease., From randomization and up to study final analysis data cut off on 28 September 2022.|Event-Free Survival (EFS) in Subpopulation With PD-L1-Postive Tumor Status, Event-free survival (EFS) defined as the time from randomization to the first documented occurrence of disease recurrence, disease progression, or death from any cause in the subpopulation with PD-L1-positive tumor status. Recurrent disease includes local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or recurrent disease., From randomization and up to study final analysis data cut off on 28 September 2022.|Disease-Free Survival (DFS) in All Participants Who Undergo Surgery, Disease-free survival (DFS) defined as the time from surgery to the first documented disease recurrence or death from any cause, whichever occurs first. DFS is analyzed with the use of the same methodology as specified for EFS for all participants., From surgery and up to study final analysis data cut off on 28 September 2022.|Disease-Free Survival (DFS) in Subpopulation of Participants With PD-L1-Positive Tumor Status Who Undergo Surgery, Disease-free survival (DFS) defined as the time from surgery to the first documented disease recurrence or death from any cause, whichever occurs first. DFS is analyzed with the use of the same methodology as specified for EFS for the subpopulation of participants with PD-L1-positive tumor status., From surgery and up to study final analysis data cut off on 28 September 2022.|Overall Survival (OS) in All Participants, Overall survival (OS) defined as the time from randomization to the date of death from any cause in all participants., From randomization and up to study final analysis data cut off on 28 September 2022.|Overall Survival (OS) in Subpopulation With PD-L1-Positive Tumor Status, Overall survival (OS) defined as the time from randomization to the date of death from any cause in the subpopulation with PD-L1-positive tumor status., From randomization and up to study final analysis data cut off on 28 September 2022.|Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30, Mean score in function (role, physical) and global health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30). The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms)., From randomization and up to study final analysis data cut off on 28 September 2022.|Mean Change From Baseline Scores for Function (Role, Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30, Mean change from baseline score in function (role, physical) and global health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30)., From randomization and up to study final analysis data cut off on 28 September 2022.|Percentage of Participants With at Least One Adverse Events (AEs), Percentage of participants with at least one adverse event., From randomization and up to study final analysis data cut off on 28 September 2022.|Minimum Observed Serum Atezolizumab Concentration (Cmin), Minimum observed serum atezolizumab concentration., Pre-dose on Day 1 of Cycles 2, 3, 4, 6, 8, 12, and 16 (cycle length = 28 days from Cycles 1 to 5, and 21 days from Cycles 6 to 16)|Maximum Observed Serum Atezolizumab Concentration (Cmax), Maximum observed atezolizumab concentration (Cmax)., Day 1 of Cycle 1 post dose (cycle length = 28 days)|Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab, Percentage of participants with anti-drug antibodies (ADAs) to atezolizumab., Baseline up to approximately 20 months",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,333,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",WO39392|2016-004734-22,2017-07-24,2020-04-03,2022-09-28,2017-06-23,2021-06-02,2023-10-26,"Stanford University Medical Center, Palo Alto, California, 94304, United States|Norwalk Hospital, Norwalk, Connecticut, 06856, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Carrollton, Georgia, 30117, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|HCA Midwest Division, Kansas City, Missouri, 64132, United States|The Valley Hospital; Valley Medical Group, Paramus, New Jersey, 07652, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, 76104, United States|Cancer Care Northwest, Spokane, Washington, 99204, United States|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, 6149, Australia|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Santa Casa de Misericordia de Salvador, Salvador, BA, 40050-410, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, 74605-070, Brazil|CETUS Hospital Dia Oncologia, Uberaba, MG, 38082-049, Brazil|Iop Instituto de Oncologia Do Parana, Curitiba, PR, 80530-010, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, 22290-160, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, 91350-200, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, 01317-001, Brazil|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, H4J 1C5, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Hochwaldkrankenhaus, Bad Nauheim, 61231, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, 10367, Germany|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, 13581, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, 33604, Germany|Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, Düsseldorf, 40235, Germany|Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum, Gelsenkirchen, 45879, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, 20357, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, 30559, Germany|Dres. Andreas Köhler und Roswitha Fuchs, Langen, 63225, Germany|St. Elisabeth-Krankenhaus, Senologie/Brustzentrum, Leipzig, 04277, Germany|Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, 80336, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, 48149, Germany|Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH, Oldenburg, 26133, Germany|Irccs Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Ospedale San Gerardo, Monza, Lombardia, 20900, Italy|Azienda ULSS 8 Berica; Oncologia Medica - Ospedlae di Vicenza, Vicenza, Veneto, 36100, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, 791-0280, Japan|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Hiroshima City Hiroshima Citizens Hospital; Breast Surgery, Hiroshima, 730-8518, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|National Hospital Organization Osaka National Hospital; Breast Surgery, Osaka, 540-0006, Japan|St. Luke's Internat. Hospital, Breast Surgical Oncology, Tokyo, 104-8560, Japan|The Cancer Inst. Hosp. of JFCR; Breast Oncology Center, Tokyo, 135-8550, Japan|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, 02-781, Poland|Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii; Oddz. Onkologii Klin. i Chemioterapii, Wroc?aw, 53-413, Poland|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, 41013, Spain|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, 00112, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, 104, Taiwan|Chang Gung Medical Foundation Linkou Branch, Taoyuan City, 333, Taiwan|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Barts & London School of Med; Medical Oncology, London, EC1A 7BE, United Kingdom|Freeman Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/35/NCT03197935/Prot_002.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/35/NCT03197935/SAP_001.pdf"
